In this work, the aim was to find high-affinity drugs against PDL1 using computational tools and conjugate nanoparticles with them. The cytotoxic activity of the nanoparticle conjugated drugs was then tested. The screening of 100,000 drugs from the ZINC database and FDA-approved drugs was done...
A comprehensive review of immune checkpoint inhibitors for cancer treatment Review 作者:Arafat Hossain, Md.;Arafat Hossain, Md Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses ...
Combinationtherapy:Inordertoovercomedrugresistanceandimprovetreatmentefficacy,PD-1/PD-L1smallmoleculeinhibitorscanbeconsideredincombinationwithotherdrugs(suchaschemotherapydrugs,targeteddrugs,etc.).Throughcombinationtherapy,thesynergisticeffectbetweendifferentdrugscanbeutilizedtoimprovetreatmentefficacyandreducedrugresistance....
Immune checkpoint inhibitors (ICIs) have been approved for treating various cancers; however, they can cause immune-related adverse events. Generally, ICIs are not associated with an increased risk of infection, however, several reports demonstrated infections caused by nontuberculous mycobacterium (NTM)...
[Abstract]Background and purpose:The immunogenic drugs represented by programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) have achieved great success in clinic. However, with the development of cli...
In metastatic non-small cell lung carcinoma (NSCLC) without alterations in oncogenic drivers, platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) targeting the programmed death-1/programmed death-ligand 1 (PD1/PDL1) ... LB Somme,C Chouaid,F Moinard-Butot,... - 《Biodrugs》 被...
However, there are major challenges associated with these immunohistochemistry tests which have opened the space for noninvasive imaging modalities using PD1 and PDL1 inhibitors labeled with either PET or SPECT radionuclides. These radiopharmaceuticals, although primarily developed for the field of ...
(Fig.1). Many approved drugs are aimed at binding to and blocking either PD-1 or PD-L1 that stops receptor-ligand binding and will allow the T-cell to continue with killing foreign tumor cells. These drugs have shown therapeutic success in both primary and metastatic cancers8,9; however,...
while "immune checkpoint inhibitors," "tumor immune microenvironment," "tertiary lymphoid structures" and "durvalumab" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymp...
PDL1smallmoleculeinhibitorshasbecomeahotspotin thedevelopmentofnewdrugsInthispaper牞thebiologicalmechanismsofPD1/PDL1wasintroducedindetail. Basedonthestructuralclassification牞theresearchprogressofPD1/PDL1smallmoleculeinhibitorswas reviewed牞withaprospectofthedevelopmentofsmallmoleculeinhibitors Keywordstumorimmunology牷...